Laura Sepp-Lorenzino - Mar 1, 2022 Form 4/A - Amendment Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
EVP, Chief Scientific Officer
Signature
/s/ James Basta, attorney-in-fact
Stock symbol
NTLA
Transactions as of
Mar 1, 2022
Transactions value $
$0
Form type
4/A - Amendment
Date filed
3/4/2022, 07:58 PM
Date Of Original Report
Mar 3, 2022
Previous filing
Mar 3, 2022
Next filing
Jun 22, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NTLA Stock Option (right to buy) Award $0 +20.2K $0.00 20.2K Mar 1, 2022 Common Stock 20.2K $79.85 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The original Form 4 incorrectly reported the number of options granted as 13,816.
F2 This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.